Hemab Therapeutics Holdings, Inc. (NasdaqGS: COAG)
Health Care · Biotechnology · US
$49.65
+6.39% today · +46.0% 1Y
Hemab Therapeutics Holdings, Inc. (NasdaqGS: COAG) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.32B and employs 59 people.
Over the last twelve months the share price has gained 46.0%, trading between 23.00 and 55.42.
COAG price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.32B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -10.06
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $55.42
- 52-week low
- $23.00
- Avg volume (3M)
- —
- Shares outstanding
- 46.71M
- Employees
- 59
- Next earnings
- —
About Hemab Therapeutics Holdings, Inc.
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
- ISIN
- US4234941031
- Founded
- 2020
- Listed since
- May 1, 2026
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.83 | +14.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.